{"nctId":"NCT00365859","briefTitle":"Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","startDateStruct":{"date":"2006-09"},"conditions":["Autistic Disorder","Behavioral Symptoms"],"count":330,"armGroups":[{"label":"De Novo","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"Rollover Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]},{"label":"Rollover Aripiprazole","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole"]}],"interventions":[{"name":"Aripiprazole","otherNames":["Abilify","BMS-337039"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria - Rollover:\n\n* Completed 8 weeks of treatment in one of the following double-blind clinical trials: CN138-178 \\[NCT00332241\\] or CN138-179 \\[NCT00337571\\]\n* No significant protocol violations and sufficient medical justification to continue on open-label treatment with aripiprazole\n\nInclusion Criteria - De Novo:\n\n* Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) diagnostic criteria for AD and demonstrates serious behavioral problems - diagnosis confirmed by Autism Diagnostic Interview-Revised (ADI-R) or the patient meets the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) diagnostic criteria for AD and has a history of behavioral problems that are currently being treated with psychotropic medication\n* Mental age of at least 18 months\n* Male or female 6 to 17 years of age, inclusive, at the time of enrollment\n\nExclusion Criteria:\n\n* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each\n* Patients previously treated and not responding to aripiprazole treatment\n* The patient is currently diagnosed with another disorder on the autism spectrum, including pervasive developmental disorder-not otherwise specified (PDD-NOS), Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder\n* Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression\n* A seizure in the past year\n* History of severe head trauma or stroke\n* Non-pharmacologic therapy (e.g. psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs","description":"Participants with Adverse Events (AEs), Deaths, Serious AEs (SAEs), and AEs leading to study discontinuation. AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"148","spread":null},{"groupId":"OG003","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52","description":"The SAS is a 10-item instrument used to evaluate the presence and severity of parkinsonian symptomatology. It is the most commonly used rating scale for Parkinsonism in clinical trials over the past 25 years. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The total SAS Score has a possible range from 10 to 50. Negative change scores indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"1.40"},{"groupId":"OG001","value":"10.6","spread":"1.17"},{"groupId":"OG002","value":"11.0","spread":"2.11"},{"groupId":"OG003","value":"10.8","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.13"},{"groupId":"OG001","value":"0.1","spread":"1.51"},{"groupId":"OG002","value":"-0.4","spread":"2.12"},{"groupId":"OG003","value":"-0.2","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.59"},{"groupId":"OG001","value":"0.2","spread":"1.42"},{"groupId":"OG002","value":"-0.6","spread":"1.96"},{"groupId":"OG003","value":"-0.3","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.44"},{"groupId":"OG001","value":"0.3","spread":"1.80"},{"groupId":"OG002","value":"-0.5","spread":"1.82"},{"groupId":"OG003","value":"-0.3","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.70"},{"groupId":"OG001","value":"0.3","spread":"1.59"},{"groupId":"OG002","value":"-0.3","spread":"2.06"},{"groupId":"OG003","value":"-0.1","spread":"1.89"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52","description":"The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs and 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in 3 main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0=none, 4=severe). The AIMS Total Score has a possible range from 0 to 28. Negative change scores indicate improvement in movement dysfunction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.90"},{"groupId":"OG001","value":"0.5","spread":"1.02"},{"groupId":"OG002","value":"0.3","spread":"1.23"},{"groupId":"OG003","value":"0.4","spread":"1.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.45"},{"groupId":"OG001","value":"-0.1","spread":"0.87"},{"groupId":"OG002","value":"-0.1","spread":"1.15"},{"groupId":"OG003","value":"-0.2","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.37"},{"groupId":"OG001","value":"-0.0","spread":"1.30"},{"groupId":"OG002","value":"-0.2","spread":"1.26"},{"groupId":"OG003","value":"-0.2","spread":"1.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.44"},{"groupId":"OG001","value":"-0.0","spread":"1.00"},{"groupId":"OG002","value":"-0.1","spread":"1.13"},{"groupId":"OG003","value":"-0.2","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.33"},{"groupId":"OG001","value":"0.0","spread":"1.44"},{"groupId":"OG002","value":"-0.1","spread":"1.32"},{"groupId":"OG003","value":"-0.1","spread":"1.35"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint","description":"The Barnes Akathisia Rating Scale is a 4-item scale to assess presence and severity of drug-induced akathisia, including both objective items and subjective items, together with a global clinical assessment of akathisia. Global assessment is made on a scale of 0 to 5 with comprehensive definitions provided for each anchor point on scale: 0=absent; 1=questionable; 2=mild akathisia; 3=moderate akathisia; 4=marked akathisia; 5=severe akathisia. Score has a possible range from 0 (absent) to 5 (severe akathisia). Negative change scores indicate improvement in akathisia.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.57"},{"groupId":"OG001","value":"0.2","spread":"0.54"},{"groupId":"OG002","value":"0.1","spread":"0.41"},{"groupId":"OG003","value":"0.1","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.55"},{"groupId":"OG001","value":"-0.1","spread":"0.50"},{"groupId":"OG002","value":"0.0","spread":"0.35"},{"groupId":"OG003","value":"0.0","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.64"},{"groupId":"OG001","value":"-0.1","spread":"0.48"},{"groupId":"OG002","value":"0.0","spread":"0.41"},{"groupId":"OG003","value":"0.0","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.37"},{"groupId":"OG001","value":"0.0","spread":"0.49"},{"groupId":"OG002","value":"0.1","spread":"0.56"},{"groupId":"OG003","value":"0.0","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.67"},{"groupId":"OG001","value":"0.0","spread":"0.52"},{"groupId":"OG002","value":"0.1","spread":"0.58"},{"groupId":"OG003","value":"0.0","spread":"0.59"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities","description":"Abnormal metabolic criterion values include the following: fasting serum glucose ≥115 mg/dL; non-fasting serum glucose ≥ 200 mg/dL; total cholesterol ≥240 mg/dL; LDL cholesterol ≥160 mg/dL; HDL cholesterol ≤30 mg/dL; triglycerides ≥120 mg/dL (females), ≥160 mg/dL (males)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities","description":"Abnormal hematology criterion values include the following: hematocrit (ages 6-17, males \\& females) ≤33%; hemoglobin (ages 6-17, males \\& females) \\<11.3 g/dL; leukocytes ≤2800 c/mm3 or ≥16000 c/mm3; eosinophils (ages 6-17, males \\& females) \\>17%; neutrophils \\<15%; platelet count ≤75,000 c/mm3 or ≥700,000 c/mm3","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities","description":"Abnormal chemistry criterion values include the following: aspartate aminotransferase ≥3x upper limit of normal (ULN); alanine aminotransferase ≥3x ULN; alkaline phosphatase ≥3x ULN; lactate dehydrogenase ≥3x ULN; creatinine ≥2.0 mg/dL; uric acid, ≥10.5 mg/dL (male), ≥8.5 mg/dL (female); bilirubin (Total) ≥2.0 mg/dL; serum prolactin \\>ULN; creatine kinase ≥3x ULN; blood urea nitrogen ≥30 mg/dL; sodium ≤126 mEq/L or ≥156 mEq/L; potassium ≤2.5 mEq/L or ≥ 6.5 mEq/L; chloride ≤90 mEq/L or ≥118 mEq/L; calcium ≤8.2 mg/dL or ≥12 mg/dL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities","description":"These abbreviations are used in the table of ECG measurements: supraventricular (SV), baseline (BL), 1 degree (1°), atrioventricular (A-V), intraventricular (IVT), symmetrical (SYM), corrected QT interval (QTc). QRS complex is a recording of a single heartbeat on ECG corresponding to the depolarization of the right and left ventricles. PR interval is measured from beginning of P wave to beginning of QRS complex. QT interval is a measure of time between start of Q wave and end of T wave in the heart's electrical cycle. ↑ = increase from baseline, ↓ = decrease from baseline, → = \"to\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Potentially Clinically Relevant Vital Sign Abnormalities","description":"Clinically significantly abnormal vital signs met age-appropriate (heart rate cohorts: ages 5-14 \\& ages 15+; blood pressure cohorts: ages 6-12 \\& ages 13-17) criterion AND represented change from pretreatment value of at least the following magnitudes: systolic blood pressure (≥130 mmHg \\& ≥144 mmHg w/ increase of ≥20 mmHg) or (≤117 mmHg \\& ≤120 mmHg w/ decrease of ≥20 mmHg); diastolic blood pressure (≥86 mmHg \\& ≥92 mmHg w/ increase of ≥15 mmHg) or (≤75 mm Hg \\& ≤80 mmHg w/ decrease of ≥15 mmHg); heart rate (140 bpm and 120 bpm w/ increase of ≥15 bpm) or (50 bpm and 50 bpm w/ decrease of ≥15 bpm).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Patient Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":"23.17"},{"groupId":"OG001","value":"45.1","spread":"20.37"},{"groupId":"OG002","value":"45.4","spread":"21.79"},{"groupId":"OG003","value":"44.6","spread":"21.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.76"},{"groupId":"OG001","value":"-0.1","spread":"1.06"},{"groupId":"OG002","value":"0.4","spread":"0.94"},{"groupId":"OG003","value":"0.3","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.99"},{"groupId":"OG001","value":"0.0","spread":"1.47"},{"groupId":"OG002","value":"0.8","spread":"1.15"},{"groupId":"OG003","value":"0.5","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.26"},{"groupId":"OG001","value":"0.5","spread":"1.60"},{"groupId":"OG002","value":"1.2","spread":"1.43"},{"groupId":"OG003","value":"1.0","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.99"},{"groupId":"OG001","value":"1.5","spread":"2.29"},{"groupId":"OG002","value":"1.9","spread":"2.09"},{"groupId":"OG003","value":"1.8","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"2.81"},{"groupId":"OG001","value":"2.8","spread":"2.79"},{"groupId":"OG002","value":"3.1","spread":"2.80"},{"groupId":"OG003","value":"3.1","spread":"2.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"3.39"},{"groupId":"OG001","value":"3.3","spread":"4.73"},{"groupId":"OG002","value":"4.2","spread":"3.34"},{"groupId":"OG003","value":"4.0","spread":"3.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"4.41"},{"groupId":"OG001","value":"4.7","spread":"4.36"},{"groupId":"OG002","value":"4.9","spread":"3.99"},{"groupId":"OG003","value":"4.9","spread":"4.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"5.80"},{"groupId":"OG001","value":"5.8","spread":"4.90"},{"groupId":"OG002","value":"6.1","spread":"4.68"},{"groupId":"OG003","value":"6.0","spread":"5.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"6.46"},{"groupId":"OG001","value":"6.4","spread":"5.90"},{"groupId":"OG002","value":"7.1","spread":"5.11"},{"groupId":"OG003","value":"6.9","spread":"5.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"6.77"},{"groupId":"OG001","value":"7.7","spread":"6.44"},{"groupId":"OG002","value":"7.9","spread":"5.90"},{"groupId":"OG003","value":"8.1","spread":"6.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"6.71"},{"groupId":"OG001","value":"5.5","spread":"5.50"},{"groupId":"OG002","value":"6.6","spread":"5.72"},{"groupId":"OG003","value":"6.3","spread":"5.94"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline by Time Period in Body Weight Z-Score","description":"The Z-Score indicates how many standard deviations a person is from the population norm values. The body weight z-scores are designed to take into account the amount of weight gain that would be expected due to normal growth in children and adolescents. The body weight z-scores are by age and gender standardized values (corresponding to a normal distribution with mean 0 and a standard deviation of 1) of the actual weight measurements, based on the Growth Charts provided by the Centers for Disease Control (CDC; see Links section of this record).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"1.687"},{"groupId":"OG001","value":"0.95","spread":"1.112"},{"groupId":"OG002","value":"0.98","spread":"1.392"},{"groupId":"OG003","value":"0.84","spread":"1.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.283"},{"groupId":"OG001","value":"0.10","spread":"0.204"},{"groupId":"OG002","value":"0.09","spread":"0.300"},{"groupId":"OG003","value":"0.10","spread":"0.277"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.433"},{"groupId":"OG001","value":"0.26","spread":"0.331"},{"groupId":"OG002","value":"0.20","spread":"0.327"},{"groupId":"OG003","value":"0.22","spread":"0.359"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.570"},{"groupId":"OG001","value":"0.28","spread":"0.367"},{"groupId":"OG002","value":"0.23","spread":"0.407"},{"groupId":"OG003","value":"0.26","spread":"0.448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.580"},{"groupId":"OG001","value":"0.23","spread":"0.399"},{"groupId":"OG002","value":"0.24","spread":"0.465"},{"groupId":"OG003","value":"0.26","spread":"0.486"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Patient Body Mass Index (BMI)","description":"The body mass index (BMI) is a statistical measurement which compares a person's weight and height. Though it does not actually measure the percentage of body fat, it is used to estimate a healthy body weight based on subject height.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"6.31"},{"groupId":"OG001","value":"21.0","spread":"5.15"},{"groupId":"OG002","value":"21.6","spread":"6.38"},{"groupId":"OG003","value":"21.1","spread":"6.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.56"},{"groupId":"OG001","value":"1.4","spread":"2.07"},{"groupId":"OG002","value":"1.8","spread":"2.51"},{"groupId":"OG003","value":"1.7","spread":"2.43"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline By Time Period in BMI Z-Score","description":"The Z-Score indicates how many standard deviations a person is from the population norm values. The BMI z-scores are designed to take into account the BMI that would be expected due to normal growth in children and adolescents. The BMI z-scores are by age and gender standardized values (corresponding to a normal distribution with mean 0 and a standard deviation of 1) of the actual BMI measurements, based on the Growth Charts provided by the Centers for Disease Control (CDC; see Links section of this record).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"1.591"},{"groupId":"OG001","value":"0.98","spread":"0.997"},{"groupId":"OG002","value":"1.01","spread":"1.236"},{"groupId":"OG003","value":"0.86","spread":"1.313"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.436"},{"groupId":"OG001","value":"0.12","spread":"0.268"},{"groupId":"OG002","value":"0.09","spread":"0.500"},{"groupId":"OG003","value":"0.12","spread":"0.443"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.625"},{"groupId":"OG001","value":"0.28","spread":"0.388"},{"groupId":"OG002","value":"0.18","spread":"0.549"},{"groupId":"OG003","value":"0.23","spread":"0.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.647"},{"groupId":"OG001","value":"0.24","spread":"0.438"},{"groupId":"OG002","value":"0.18","spread":"0.643"},{"groupId":"OG003","value":"0.24","spread":"0.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.768"},{"groupId":"OG001","value":"0.15","spread":"0.476"},{"groupId":"OG002","value":"0.14","spread":"0.775"},{"groupId":"OG003","value":"0.19","spread":"0.725"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)","description":"CGI scale is a global evaluation of improvement over time. CGI-Severity (CGI-S) is a clinician-rated assessment that evaluates the severity of a patient's condition on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). CGI-Severity score is from 1 to 7. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"0.99"},{"groupId":"OG001","value":"4.2","spread":"0.99"},{"groupId":"OG002","value":"3.9","spread":"1.05"},{"groupId":"OG003","value":"4.2","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.85"},{"groupId":"OG001","value":"-0.4","spread":"1.06"},{"groupId":"OG002","value":"-0.0","spread":"1.01"},{"groupId":"OG003","value":"-0.3","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"CGI-Improvement Score at Week 52 (Endpoint, LOCF)","description":"CGI scale is a global evaluation of improvement over time. CGI-Improvement (CGI-I) is a clinician rated assessment that evaluates improvement relative to symptoms at baseline on a a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). CGI-I Score is from 1 to 7. A lower score signifies larger improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.30"},{"groupId":"OG001","value":"2.4","spread":"1.24"},{"groupId":"OG002","value":"2.5","spread":"1.20"},{"groupId":"OG003","value":"2.5","spread":"1.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)","description":"The ABC is an informant-based symptom checklist for assessing and classifying problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0 = not at all a problem to 3 = the problem is severe in degree), and resolve into 5 subscales: (1) irritability and agitation; (2) lethargy and social withdrawal; (3) stereotypic behavior; (4) hyperactivity and noncompliance, and (5) inappropriate speech. ABC Irritability Subscale Score is from 0 to 45. A negative change signifies improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"8.88"},{"groupId":"OG001","value":"21.5","spread":"9.82"},{"groupId":"OG002","value":"15.0","spread":"9.20"},{"groupId":"OG003","value":"18.5","spread":"9.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"11.12"},{"groupId":"OG001","value":"-6.1","spread":"11.25"},{"groupId":"OG002","value":"0.7","spread":"9.72"},{"groupId":"OG003","value":"-2.6","spread":"10.98"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)","description":"The ABC is an informant-based symptom checklist for assessing and classifying problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0 = not at all a problem to 3 = the problem is severe in degree), and resolve into 5 subscales: (1) irritability and agitation; (2) lethargy and social withdrawal; (3) stereotypic behavior; (4) hyperactivity and noncompliance, and (5) inappropriate speech. ABC Hyperactivity Subscale Score is from 0 to 48. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":"10.87"},{"groupId":"OG001","value":"25.8","spread":"13.18"},{"groupId":"OG002","value":"18.4","spread":"12.03"},{"groupId":"OG003","value":"22.5","spread":"12.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"10.55"},{"groupId":"OG001","value":"-8.3","spread":"10.85"},{"groupId":"OG002","value":"0.3","spread":"11.18"},{"groupId":"OG003","value":"-4.2","spread":"11.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)","description":"The ABC is an informant-based symptom checklist for assessing and classifying problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0 = not at all a problem to 3 = the problem is severe in degree), and resolve into 5 subscales: (1) irritability and agitation; (2) lethargy and social withdrawal; (3) stereotypic behavior; (4) hyperactivity and noncompliance, and (5) inappropriate speech. ABC Stereotypy Subscale Score is from 0 to 21. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"5.18"},{"groupId":"OG001","value":"8.1","spread":"5.57"},{"groupId":"OG002","value":"6.4","spread":"5.46"},{"groupId":"OG003","value":"7.2","spread":"5.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"4.67"},{"groupId":"OG001","value":"-1.9","spread":"4.46"},{"groupId":"OG002","value":"0.1","spread":"4.58"},{"groupId":"OG003","value":"-1.0","spread":"4.71"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)","description":"The ABC is an informant-based symptom checklist for assessing and classifying problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0 = not at all a problem to 3 = the problem is severe in degree), and resolve into 5 subscales: (1) irritability and agitation; (2) lethargy and social withdrawal; (3) stereotypic behavior; (4) hyperactivity and noncompliance, and (5) inappropriate speech. ABC Social Withdrawal Subscale Score is from 0 to 48. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":"8.62"},{"groupId":"OG001","value":"11.3","spread":"9.24"},{"groupId":"OG002","value":"10.4","spread":"8.86"},{"groupId":"OG003","value":"11.7","spread":"9.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"9.07"},{"groupId":"OG001","value":"-3.0","spread":"6.96"},{"groupId":"OG002","value":"-1.8","spread":"6.09"},{"groupId":"OG003","value":"-3.0","spread":"7.28"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)","description":"The ABC is an informant-based symptom checklist for assessing and classifying problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0 = not at all a problem to 3 = the problem is severe in degree), and resolve into 5 subscales: (1) irritability and agitation; (2) lethargy and social withdrawal; (3) stereotypic behavior; (4) hyperactivity and noncompliance, and (5) inappropriate speech. ABC Inappropriate Speech Subscale score is from 1 to 12. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"3.15"},{"groupId":"OG001","value":"5.7","spread":"4.23"},{"groupId":"OG002","value":"4.2","spread":"3.61"},{"groupId":"OG003","value":"4.9","spread":"3.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"2.66"},{"groupId":"OG001","value":"-1.8","spread":"2.94"},{"groupId":"OG002","value":"-0.3","spread":"2.50"},{"groupId":"OG003","value":"-1.0","spread":"2.75"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)","description":"CY-BOCS is a 10-item, clinician-rated scale designed to measure the severity of obsessive-compulsive symptoms in patients below the age of 18. The scale contains 5 items pertaining to obsessions (which were not used in this trial) and 5 items pertaining to compulsions, which rated each symptom domain in terms of time spent, interference with functioning, distress, resistance, and control. Each item was rated on a 5-point scale, from 0 (no symptoms or minimum severity) to 4 (extreme symptoms or maximum severity). CY-BOCS Score is from 0 to 20. A negative change score signifies improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"4.60"},{"groupId":"OG001","value":"12.1","spread":"3.96"},{"groupId":"OG002","value":"10.4","spread":"3.87"},{"groupId":"OG003","value":"11.4","spread":"4.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"3.68"},{"groupId":"OG001","value":"-2.4","spread":"5.06"},{"groupId":"OG002","value":"0.2","spread":"3.81"},{"groupId":"OG003","value":"-0.9","spread":"4.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":86},"commonTop":["WEIGHT INCREASED","VOMITING","NASOPHARYNGITIS","INCREASED APPETITE","PYREXIA"]}}}